The results of the All-Russian multicenter study of the use of the antitussive drug Codelac® Broncho in patients with productive cough; [Результаты Всероссийского многоцентрового исследования применения комбинированного препарата Коделак® Бронхо у пациентов с продуктивным кашлем]

Cough in therapeutic and pediatric practice continues to be one of the most prevalent reasons for patients seeking outpatient care. Therefore, it is essential to pay particular attention to the selection of medications that effectively and safely treat a productive cough, which may adversely affect a patient’s quality of life. The aim of this study is to examine the current clinical practice of using the combination drug Codelac® Broncho in outpatients, which contains ambroxol, sodium bicarbonate, sodium glycyrrhizinate, and extracts from thermopsis lanceolate. The study focuses on patients with a productive cough who receive this medication as monotherapy or part of a comprehensive treatment regimen prescribed by physicians in therapeutic and pediatric clinics. Material and methods. We analyzed data from 26,896 anonymized patient surveys with a productive cough completed by research physicians participating in the study. Of these, 13 149 were from internists and 13 747 were from pediatricians. Following the application of inclusion criteria, 14 336 surveys were selected for further analysis. These surveys included patients of both genders with a productive cough who had not taken antibiotics. The data analyzed included the dynamics of transition from a productive cough to residual cough or absence of cough, as well as severity of cough during the night and day, and auscultatory findings on days three, four, five, and seven of treatment. Results and discussion. Codelac® Broncho has been shown to have a positive impact on the findings of auscultation, the nature and severity of productive cough. During treatment, positive changes in the transformation of productive cough into residual cough or relief were noted in 92.3% of children and 82.4% of adults after 3–4 days, and 100 and 97.6%, respectively, after 5–7 days. The average severity of cough decreased from 2.9 (out of 3) points to 2.5 in children and 2.3 points in adults after 3–4 days. Positive changes in findings of auscultation were observed in 62% of children and 37% of adults early (after 3–4 days), and 95% and 90%, respectively, after 7 days. Similar results were obtained for severity of nighttime and daytime cough. No adverse events were reported. Conclusion. The use of Codelac® Broncho, a combination drug, in patients with productive cough is safe and results in a significant improvement of symptoms. This was observed in outpatient settings. © 2024 Geotar Media Publishing Group. All rights reserved.